Mass Spectrometry Imaging Market
Report ID: SQMIG35J2224
Report ID: SQMIG35J2224
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2224 |
Region:
Global |
Published Date: February, 2026
Pages:
157
|Tables:
121
|Figures:
77
Global Mass Spectrometry Imaging Market size was valued at USD 3.0 Billion in 2024 and is poised to grow from USD 3.27 Billion in 2025 to USD 6.57 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).
The key trend driving the global mass spectrometry imaging sector is the expanding need for spatially resolved molecular information in life sciences and clinical research. Mass Spectrometry Imaging (MSI) uses Mass Spectrometry and Imaging to develop a visual representation or map of metabolites, lipids, peptides and drugs on tissue samples allowing researchers to see information that is not available from conventional bulk analyses. This new methodology is significant because of how it speeds up biomarker discovery, assists with delineating surgical margins, and provides information that will lead to more targeted and personalized treatment regimens have been validated through studies in cancer to differentiate between tumour sub regions.
Rising vendor investment and advances in ionization methods and software have directly expanded market adoption because enhanced sensitivity and spatial resolution produce clinically actionable data faster. As instruments became more robust and user-friendly, pharmaceutical companies integrated imaging for drug distribution studies, which reduced candidate failure risk and accelerated trial design. Consequently, service providers offer standardized workflows and imaging-as-a-service models that lower entry barriers, creating opportunities in diagnostics, precision oncology and regulatory-compliant biomarker validation across global markets boosting adoption.
How is AI Enhancing Clinical Applications in the Mass Spectrometry Imaging Market?
AI is transforming clinical mass spectrometry imaging by streamlining data interpretation, enhancing spatial resolution, and supporting biomarker discovery. Spectral deconvolution is an example of an automated workflow used for data analysis. The integration of pattern recognition capabilities and clinical elements into workflows makes the use of AI easier for pathology and pharmacology professionals. These technologies have provided a consistent and rapid turnaround time for generating clinically applicable reports by converting complex molecular data into relevant reports for clinicians. Tumor margin identification using machine learning models on mass spectrometry imaging and the standardization of sample preparation methods and analysis using AI-supported pipelines.
Market snapshot - 2026-2033
Global Market Size
USD 3.0 Billion
Largest Segment
Instruments
Fastest Growth
Services
Growth Rate
9.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global mass spectrometry imaging market is segmented by product type, technology, application, end-user and region. Based on product type, the market is segmented into instruments, consumables, and services. Based on technology, the market is segmented into matrix-assisted laser desorption or ionization (MALDI), secondary ion mass spectrometry (SIMS), desorption electrospray ionization (DESI), magnetic sector mass spectrometry, time-of-flight mass spectrometry (TOFMS) and other technologies. Based on application, the market is segmented into proteomics, metabolomics, glycomics, and other applications. Based on end-user, the market is segmented into pharmaceutical and biotechnology companies, government and academic institutions and other end-users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Based on the global mass spectrometry imaging market forecast, MALDI segment dominates because its soft ionization and tissue compatible workflows enable high quality molecular mapping of proteins and metabolites across diverse biological samples. The use of instruments supplied by a known vendor or group of vendors will provide standardised sample preparation methods across multiple vendors. This in turn would (and currently does) establish familiarity amongst researchers conducting studies in biomarker discovery and translational research. Continuous methodological refinements and strong integration with proteomics pipelines reinforce its leadership, creating a self reinforcing preference that shapes purchasing and project design.
However, DESI is emerging as the most rapidly expanding technology owing to ambient ionization that allows minimal sample preparation and direct surface analysis of biological and clinical specimens. Growing interest in rapid clinical workflows, instrument miniaturization, and cross disciplinary applications in metabolomics and forensics is accelerating adoption and unlocking new application driven opportunities.
Consumables segment dominates because recurring needs for specialized matrices, target plates, and calibrated standards underpin routine mass spectrometry imaging operations across laboratories. The kits used to prepare proprietary samples, as well as the reagents that have been optimized and the disposables approved/validated by vendors themselves, all contribute to ensuring reliable/reproducible results from a variety of branded products. By continuing to develop application-specific consumables, the barriers to adoption are lowered, there is an increased degree of standardisation in workflows and an ongoing stream of revenue for vendors which will continue to maintain the investment within the vendor ecosystem.
However, services are witnessing the strongest growth momentum as laboratory outsourcing, specialized imaging contracts, and complex data interpretation needs increase. Demand for contract research, clinical validation studies, and turnkey imaging solutions is rising, enabling smaller institutions to access advanced capabilities and creating new revenue streams for providers while accelerating translational projects and commercial collaborations.
To get detailed segments analysis, Request a Free Sample Report
As per the global mass spectrometry imaging market analysis, North America commands the industry through a convergence of robust research infrastructure, leading instrument manufacturers, and deep clinical and industrial adoption. Method development/validation is driven by translational research programs and academic centers, whereas imaging is incorporated into drug discovery and biomarker efforts by pharmaceutical and biotechnology firms. Pathways to regulatory approval and reimbursement mechanisms in principal markets enable clinical research and adoption, while the concentration of specialist service labs and collaborations with pathologists contributes to commercialization. Manufacturers have established design, support, and training resources in the region so they can rapidly deploy products and provide aftermarket support.
Mass spectrometry imaging market in United States benefits from a dense concentration of academic medical centers, pharmaceutical headquarters, and instrument manufacturers that foster rapid method translation and commercialization. Many specialized service providers; and proximity/ease of access to regulatory bodies. Accelerated adoption will occur as a result of strong vendor support and collaborative consortia.
Mass spectrometry imaging market in Canada is characterized by strong public research institutions, collaborative provincial networks, and growing clinical research capacity that bridge discovery and applied use. Collaboration among universities, hospitals and technological vendors can result in innovative and custom designed approaches towards biomarker identification and integration of pathology into existing systems. By emphasizing on training, open data programs, as well as cross border partnerships, we can build regional capability & maturity of the market. Vendor support and collaborations nurture practical uptake across institutions broadly.
Europe is experiencing rapid expansion in the mass spectrometry imaging market due to a combination of concentrated scientific expertise, coordinated funding initiatives, and active collaboration between academia, industry, and clinical stakeholders. There is increasing demand for hardware and service provision by national research centers and pharmaceutical hubs which are prioritizing translational projects incorporating imaging into drug discovery and clinical validation processes. Specialized vendors, pathology laboratories and consortia have created a robust network facilitating standardization, data sharing and training. As a result of efforts to reduce barriers to adoption and enhance market penetration in therapeutic areas, there is significant clinical translation and potential to scale commercially in Europe.
Mass spectrometry imaging market in Germany is anchored by a strong industrial and academic ecosystem, with major instrument companies, technical universities, and specialized research centers collaborating on application development. Strong connections to the pharmaceutical and diagnostic industries allow for rigorous validation, as well as trained technicians to speed adoption into clinical and industrial workflows. The creation of local consortia and vendor networks also helps reduce the "friction" associated with adopting these types of technologies and ultimately leads to new ways of using these types of technologies in various research areas within the therapeutic space.
Mass spectrometry imaging market in United Kingdom is propelled by dynamic translational research networks, prominent biomedical clusters, and active clinical trial activity that accelerate adoption across research and healthcare settings. The universities, the hospital pathology services, and the innovative vendors work closely together to develop new technologies quickly and successfully. Having supportive policy frameworks, collaborative consortiums, and an entrepreneurial ecosystem, facilitates the translation of prototypes into large-scale services and clinical workflows for regional adoption and ultimately enhances patient-centred integrative research.
Mass spectrometry imaging market in France is developing through concentrated academic excellence, national research networks, and targeted collaborations that move promising methods toward clinical application. Emerging vendor activity and incubator programs support startup innovation, while pathology partnerships enable pilot studies in oncology and biomarker discovery. Focus on harmonized protocols, training, and data interoperability will be important to scale capabilities and attract broader commercial engagement across research and clinical sectors nationwide.
Asia Pacific is strengthening its position in the mass spectrometry imaging market through strategic investments in research infrastructure, localized manufacturing capabilities, and growing collaboration between academic, clinical, and commercial actors. While established life sciences centres continue to build optimizing methods and the development of instrumentation, health systems are integrating imaging into their diagnostic and translational research agendas, driving demand for new equipment. There are regional partnerships or alliances within which one would find a vendor investment effort related to providing a local support mechanism that is creating opportunities for utilising the technology. Emphasis on training and data standards will contribute to removing barriers to the use of technology and supporting broader use within pharmaceutical research, clinical pathology and industrial applications.
Mass spectrometry imaging market in Japan is supported by advanced instrument engineering, strong academic hospital networks, and close collaboration with domestic pharmaceutical and diagnostics companies that drive application sophistication. The concentration on precision, quality management systems, and automation allows for clinical research and industrial workflow integration while using local vendors' services to support implementation and maintenance efforts. International partnerships are fostered through active collaboration and investments in training to translate technical capability into clinical impact and offerings.
Mass spectrometry imaging market share in South Korea is driven by a vibrant technology ecosystem, strong biomedical research institutions, and agile instrument and software vendors that tailor solutions to local clinical and industrial needs. Close partnerships between hospitals, universities, and startups accelerate translational projects, while emphasis on digital workflows and data integration supports scalable adoption. Government funded programs and export oriented manufacturers further strengthen market capability and international collaboration for expansion.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Demand In Life Sciences
Technological Advancements and Integration
High Instrumentation Costs and Maintenance
Complex Data Interpretation and Expertise
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape in global mass spectrometry imaging outlook is consolidated via targeted software and platform acquisitions, strategic distribution partnerships, and accelerated product innovation by instrument vendors and spatial omics startups. Market drivers tied to competition include integration of data analysis into instrument portfolios and go to market alliances, exemplified by Bruker’s acquisition of SCiLS and recent distribution and product launches by emerging spatial biology companies.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global mass spectrometry imaging industry is propelled primarily by expanding demand for spatially resolved molecular information in life sciences and clinical research, which accelerates biomarker discovery and translational studies. Due to costly instruments and maintenance costs, their use is limited, particularly in smaller labs, but North America has a very robust supply of marketplace research facilities and therefore it has the largest volume of usage by researchers globally, plus the MALDI technology sector will be the premier sector of the research marketplace because it uses tissue approved methods and uses standard operating procedures (SOPs) for operation. Furthermore, vendor investments in delivery, ionization methods, and software development will enhance performance characteristics such as detection limits, throughput rates, and clinical utility.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 3.0 Billion |
| Market size value in 2033 | USD 6.57 Billion |
| Growth Rate | 9.1% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Mass Spectrometry Imaging Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Mass Spectrometry Imaging Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Mass Spectrometry Imaging Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Mass Spectrometry Imaging Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Mass Spectrometry Imaging Market size was valued at USD 3.0 Billion in 2024 and is poised to grow from USD 3.27 Billion in 2025 to USD 6.57 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).
Competitive landscape in global mass spectrometry imaging shows consolidation via targeted software and platform acquisitions, strategic distribution partnerships, and accelerated product innovation by instrument vendors and spatial omics startups. Market drivers tied to competition include integration of data analysis into instrument portfolios and go to market alliances, exemplified by Bruker’s acquisition of SCiLS and recent distribution and product launches by emerging spatial biology companies. 'Thermo Fisher Scientific', 'Sciex', 'Waters Corporation', 'Bruker Corporation', 'Agilent Technologies', 'PerkinElmer', 'Shimadzu Corporation', 'AB Sciex', 'JEOL Ltd.', 'Aglient', 'IonBench', 'Analytik Jena', 'Vanquish', 'MassTech', 'BioTools', 'Hitachi High-Technologies Corporation', 'Hyperion', 'Tofwerk AG', 'IonQ', 'Evosep'
Spatial Multi-Omics Convergence: Integration of mass spectrometry imaging with complementary spatial omics modalities is creating richer, multidimensional molecular maps that reveal co-localized transcripts, proteins, and metabolites within tissue architecture. This convergence enhances biological understanding, expands applications in biomarker discovery and drug distribution studies, and encourages development of interoperable workflows and hybrid platforms. Collaboration between instrument vendors and software providers is driving data fusion tools and standardized pipelines, enabling broader adoption across translational research, core facilities, and interdisciplinary projects that require contextual molecular insights.
As per the global mass spectrometry imaging market analysis, North America commands the industry through a convergence of robust research infrastructure, leading instrument manufacturers, and deep clinical and industrial adoption.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
